4DMT Reports Full Year 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones

Completed enrollment in 4D-150 4FRONT-1 wet AMD Phase 3 trial within approximately 11 months, ahead of initial projections and reflecting strong interest from investigators and patients; topline data expected in H1 2027PRISM wet AMD Phase 2b 2-year data expected in mid-2026 and SPECTRA DME trial 2-year data in H2 20264D-150 DME global Phase 3 trial initiation expected in Q3 2026$514 million in cash, cash equivalents and marketable securities expected to fund current operating plan into second half of 2028 E ...